| Affiliation | Type of study | Stage of disease | Nº of BRCA1/2 mutated TNBC patients | pCR | Neoadjuvant treatment |
---|---|---|---|---|---|---|
Fontaine 2019 [26] | Belgium | RCT phase II | II-III | 9 | 7 | Cb-P + E-C |
Sella 2018 [35] | Israel | Clinical trial | I-III | 14 | 9 | Cb-P-Dox-C |
Walsh 2019 [36] | Irland | Retrospective | I-III | 6 | 4 | Cb-P + Dox-C |
Loib 2018 BrighTNess [37] | USA | RCT phase III | II-III | 24 | 12 | Cb-P- Dox-C |